You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖諾醫藥-B(02257.HK)於《皮膚病藥物雜誌》發表核心產品STP705治療成人原位鱗狀細胞皮膚癌臨牀研究結果
格隆匯 06-16 06:12

格隆匯6月16日丨聖諾醫藥-B(02257.HK)發佈公吿,公司Sirnaomics核心候選產品STP705用以治療原位鱗狀細胞皮膚癌的IIa期研究數據經同行評審後發表於《皮膚病藥物雜誌》(Journal of Drugs in Dermatology,“JDD”)。STP705是一種siRNA(小干擾核酸)藥物,可直接敲低病灶中TGF-β1 和COX-2基因表達。該研究顯示,STP705在治療原位鱗狀細胞皮膚癌(“isSCC”)患者時展現出良好的安全性和耐受性,並且在治療isSCC病變方面顯示出有效性。

《皮膚病藥物雜誌》(Journal of Drugs in Dermatology)是國際皮膚病學引領醫學刊物,主要用於呈現原研論文,獲獎的病例研究,臨牀試驗進展和完成的近況報吿,藥物和醫療設備等特殊的內容,主要針對臨牀住院醫師和輔助醫療健康專業人員。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account